ClinConnect ClinConnect Logo
Search / Trial NCT02431962

Alberta Lung Cancer Screening Program

Launched by UNIVERSITY OF CALGARY · Apr 30, 2015

Trial Information

Current as of May 04, 2025

Unknown status

Keywords

Lung Cancer Screening Computed Tomography

ClinConnect Summary

Lung cancer is the leading cause of cancer death in North America and in the world. The vast majority of lung cancers are associated with cigarette smoking. Lung cancer incidence and mortality rates are similar because lung cancer is a highly fatal disease. Unfortunately, the majority of lung cancers are detected at an advanced stage when they have a very poor prognosis. A substantial amount of data has been reported on low-dose computed tomography (LDCT) screening. The results of the National Lung Screening Trial (NLST) showed a 20% reduction in mortality from lung cancer with LDCT screeni...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects between the ages of 55 and 80 with a risk prediction model (RPM) ≥1.5% (≥ 1.5% risk of lung cancer over 6 years) OR NLST criteria (age 55-74; ≥ 30 pack-year smoking history; ongoing smoking or quit within 15 years).
  • Ability to provide informed consent and participate in study procedures.
  • Exclusion Criteria:
  • Any medical condition, such as severe heart disease (e.g. unstable angina, chronic congestive heart failure), severe lung disease or lung disease requiring supplemental oxygen that in the opinion of the physician unlikely to benefit from screening due to shortened life-expectancy from the co-morbidities or inability to tolerate diagnosis and treatment of a screen detected abnormality. European Cooperative Oncology Group performance status \> 2.
  • History of lung cancer.
  • Have had other cancer or treatment for cancer within the past 5 years with the exception of the following cancers: non-melanomatous skin cancer, localized prostate cancer, carcinoma in situ (CIS) of the cervix, or superficial bladder cancer. Treatment of the exceptions must have ended \> 6 months before registration into this study.
  • Pregnancy.
  • Hemoptysis in past 12 months.
  • Unexplained weight loss \>15 pounds / 7kg in past 12 months.
  • Unwilling to have a LDCT of chest.
  • Unwilling to sign a consent.
  • Have had a CT scan of the chest in the last 2 years.

About University Of Calgary

The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.

Locations

Edmonton, Alberta, Canada

Calgary, Alberta, Canada

Patients applied

0 patients applied

Trial Officials

Alain Tremblay, MD

Principal Investigator

University of Calgary

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials